Contemporary concepts of migraine pathogenesis

Neurology

Volumn 61, Issue 8 SUPPL., 2003, Pages

  Welch, K M A ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; FLUNARIZINE; GABAPENTIN; MAGNESIUM; PROPRANOLOL DERIVATIVE; TOPIRAMATE; VALPROIC ACID; VERAPAMIL;

BRAIN BLOOD VESSEL; BRAIN CORTEX; BRAIN NERVE CELL; BRAIN STEM; CELL ACTIVITY; CHRONIC PAIN; CONCEPT FORMATION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; HEADACHE; HUMAN; MIGRAINE; NEUROMODULATION; NOCICEPTION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TRIGEMINAL NERVE;

EID: 0345227301     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.61.8_suppl_4.s2     Document Type: Review

References (90)

1. Welch KMA, D'Andrea G, Tepley N, Barkley GL, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Headache 1990;8:817-828.
2. Aurora SK, Ahmad BK, Welch KMA, Bhardhwaj P, Ramadan NM. Transcranial magnetic stimulation confirms hyperexcitability of occipital cortex in migraine. Neurology 1998;50:1111-1114.
3. Mulleners WM, Chronicle EP, Vredeveld JW, Koehler PJ. Visual cortex excitability in migraine before and after valproate prophylaxis: a pilot study using TMS. Eur J Neurol 2002;9:35-40.
4. Young WB, Oshinsky ML, Shechter AL, Wassermann EM. Consecutive transcranial magnetic stimulation induced phosphene thresholds in migraineurs and controls. Neurology 2001;56(suppl 3):A142. Abstract.
5. Battelli L, Black KR, Wray SH. Transcranial magnetic stimulation of visual area V5 in migraine. Neurology 2002;58:1066-1069.
6. Áfra J, Mascia A, Gérard P, Maertens de Noordhout A, Schoenen J. Interictal cortical excitability in migraine: a study using transcranial magnetic stimulation of motor and visual cortices. Ann Neurol 1998;44:209-215.
7. Bowyer SM, Aurora SK, Moran JE, Tepley N, Welch KMA. Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann Neurol 2001;50:582-587.
8. Cao Y, Welch KMA, Aurora S, Vikingstad EM. Functional MRI-BOLD of visually triggered headache in patients with migraine. Arch Neurol 1999;56:548-554.
9. 2+ channel gene CACNLA4. Cell 1996;87:543-552.
10. Nyholt DR, Lea RA, Goadsby PJ, Brimage PJ, Griffiths LR. Familial typical migraine: linkage to chromosome 19p13 and evidence for genetic heterogeneity. Neurology 1998;50:1428-1432.
11. Welch KMA, Levine SR, D'Andrea G, Schultz LR, Helpern JA. Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 1989;39:538-554.
12. 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 1992;42:1209-1214.
13. Welch KMA, Ramadan NM. Mitochondria, magnesium and migraine. J Neurol Sci 1995;134:9-14.
14. Boska MD, Welch KMA, Barker PB, Nelson JA, Schultz L. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Neurology 2002;58:1227-1233.
15. Schoenen J, Jacquy J, Lenaerts M. High-dose riboflavin is effective in migraine prophylaxis: results from a double blind, randomized, placebo-controlled trial. Neurology 1997;48:A86-87.
16. Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996;16:257-263.
17. Russell MB, Rasmussen BK, Fenger K, Olesen J. Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eight-four male and female migraineurs from the general population. Cephalalgia 1996;16:239-245.
18. Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J. Prevalence and sex-ratio of the subtypes of migraine. Int J Epidemiol. 1995;24:612-618.
19. Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain 1996;119:355-361.
20. Leão AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol 1944;7:359-390.
21. Leão AAP. Pial circulation and spreading depression of activity in the cerebral cortex. J Neurophysiol 1944;7:391-396.
22. Olesen J. Cerebral and extracranial circulatory disturbances in migraine: pathophysiological implications. Cerebrovasc Brain Metab Rev 1991;3:1-28.
23. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981;9:344-352.
24. Cutrer FM, Sorensen AG, Weisskoff RM, et al. Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol 1998;43:25-31.
25. Woods RP, Iacoboni M, Mazziotta JC. Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994;331:1689-1692.
26. Hadjikhani N, Sanchez del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001;98:4687-4692.
27. Lauritzen M, Jøorgensen MB, Diemer NH, Gjedde A, Hansen AJ. Persistent oligemia of rat cerebral cortex in the wake of spreading depression. Ann Neurol 1982;12:469-474.
28. 2 response. J Cerebr Blood Flow Metab 1984;4:546-554.
29. Ingvardsen BK, Laursen H, Olsen UB, Hansen AJ. Possible mechanism of c-fos expression in trigeminal nucleus caudalis following cortical spreading depression. Pain 1997;72:407-415.
30. Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of C-fos protein-like immunoreactivity within the trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 1993;13:1167-1177.
31. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Med 2002;8:136-142.
32. Choudhuri R, Cui L, Yong C, et al. Cortical spreading depression and gene regulation: relevance to migraine. Ann Neurol 2002;51:499-506.
33. Lauritzen M. Cortical spreading depression. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The headaches. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000:189-194.
34. Moskowitz MA. Basic mechanisms in vascular headache. Neurol Clin 1990;8:801-815.
35. Read SJ, Parsons AA. Cortical spreading depression and migraine. In: Edvinsson L, ed. Migraine and headache pathophysiology. London: Martin Dunitz, 1999;81-92.
36. Grafstein B, Liu S, Cotrina ML, Goldman SA, Nedergaard M. Meningeal cells can communicate with astrocytes by calcium signaling. Ann Neurol 2000;47:18-25.
37. Aicardi G, Giuffrida R, Rapisarda C, Albe-Fessard D. Effects of cortical spreading depression on spontaneous activity of red nucleus cells in the guinea pig. Arch Ital Biol 1988;126:199-203.
38. Goadsby PJ. Pathophysiology of headache. In: Silberstein SD, Lipton RB, Solomon S, eds. Wolffs headache and other head pain. 7th ed. Oxford: Oxford University Press, 2001:57-72.
39. Feindel W, Penfield W, McNaughton F. The tentorial nerves and localization of intracranial pain in man. Neurology 1960;10:555-563.
40. Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study. J Anat 1997;190:367-375.
41. Hoskin KL, Zagami AS, Goadsby PJ. Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J Anat 1999;194:579-588.
42. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cerebr Blood Flow Metab 1999;19:115-127.
43. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 1991;44:97-112.
44. Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 1992;48:187-203.
45. Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. Annu Rev Med 1993;44:145-154.
46. Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985;62:131-136.
47. Chen LYL, Gillespie SA, Norregaard TV, Moskowitz MA. Colocalization of retrogradely transported wheat germ agglutinin and the putative neurotransmitter substance P within trigeminal ganglion cells projecting to cat middle cerebral artery. J Comp Neurol 1984;225:187-192.
48. Edvinsson L, Brodin E, Jansen I, Uddman R. Neurokinin A in cerebral vessels: characterization, localization and effects in vitro. Regul Peptides 1988;20:181-197.
49. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-187.
50. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48-56.
51. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988;23:193-196.
52. Alvarez FJ, Morris HR, Priestley JV. Sub-populations of smaller diameter trigeminal primary afferent neurons defined by expression of calcitonin gene-related peptide and the cell surface oligosaccharide recognized by monoclonal antibody LA4. J Neurocytol 1991;20:716-731.
53. Sugimoto T, Fujiyoshi Y, Xiao C, He YF, Ichikawa H. Central projection of calcitonin gene-related peptide (CGRP)- and substance P (SP)-immunoreactive trigeminal primary neurons in the rat. J Comp Neurol 1997;378:425-442.
54. Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995;15:384-390.
55. Lassen LH, Jacobsen VB, Petersen PA, Sperling B, Iversen HK, Olesen J. Human calcitonin gene-related peptide (hCGRP)-induced headache in migraineurs. Eur J Neurol 1998;5(suppl 3):S63. Abstract.
56. Buzzi MG, Bonamini M, Moskowitz MA. Neurogenic model of migraine. Cephalalgia 1995;15:277-280.
57. Roon KI, Olesen J, Diener HC, et al. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. Ann Neurol 2000;47:238-241.
58. Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000;62:509-525.
59. Goadsby PJ, Edvinsson L. Sumatriptan reverses the changes in calcitonin gene-related peptide seen in the headache phase of migraine. Cephalalgia 1991;11(suppl 11):3. Abstract.
60. Goadsby PJ, Hoskin KL. Differential effects of low dose CP122,288 and eletriptan on Fos expression due to stimulation of the superior sagittal sinus in cat. Pain 1999;82:15-22.
61. Lee WS, Moskowitz MA. Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638, exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res 1993;626:303-305.
62. Ferrari MD. Migraine. Lancet 1998;351:1043-1051.
63. Nozaki K, Moskowitz MA, Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992;106:409-415.
64. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993;109:788-792.
65. 1 antagonist CP-99,994 on plasma extravasation in the dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology 1995;34:255-261.
66. 1B/1D) receptors. Br J Pharmacol 1997;122:918-922.
67. 1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cephalalgia 1998;18:659-664.
68. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 1997;328:37-40.
69. 1B/D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain 1996;67:355-359.
70. Welch KMA, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000;20:687-695.
71. Berman N, Puri V, Cui L, Klein R, Welch KMA. Trigeminal ganglion neuropeptides cycle with ovarian steroids in a model of menstrual migraine. Headache 2002;42:438. Abstract.
72. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000;47:614-624.
73. Kaube H, Katsarava Z, Przywara S, Drepper J, Ellrich J, Diener HC. Acute migraine headache: possible sensitization of neurons in the spinal trigeminal nucleus? Neurology 2002;58:1234-1238.
74. Welch KMA, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001;41:629-637.
75. Burstein R, Collins B, Bajwa Z, Jakubowski M. Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: clinical and pre-clinical evidence. Headache 2002;42:390. Abstract.
76. Millan MJ. Descending monoaminergic modulation of pain: basic principles, novel insights from receptor multiplicity, and therapeutic perspectives. Neurosci News 2001;4:19-34.
77. Schindler M, Harris CA, Hayes B, Papotti M, Humphrey PP. Immunohistochemical localization of adenosine A1 receptors in human brain regions. Neurosci Lett 2001;297:211-215.
78. 1 receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 2002;125:1392-1401.
79. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nature Med 1995;1:658-660.
80. Ter Horst GJ, Meijler WJ, Korf J, Kemper RHA. Trigeminal nociception-induced cerebral Fos expression in the conscious rat. Cephalalgia 2001;21:963-975.
81. Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache 1987;27:416-420.
82. Veloso F, Kumar K, Toth C. Headache secondary to deep brain implantation. Headache 1998;38:507-515.
83. Haas DC, Kent PF, Friedman DI. Headache caused by a single lesion of multiple sclerosis in the periaqueductal gray area. Headache 1993;33:452-455.
84. Goadsby PJ. Neurovascular headache and a midbrain vascular malformation: evidence for a role of the brainstem in chronic migraine. Cephalalgia 2002;22:107-111.
85. Knight YE, Goadsby PJ. The periaqueductal gray matter modulates trigeminovascular input: a role in migraine? Neuroscience 2001;106:793-800.
86. Knight YE, Bartsch T, Kaube H, Goadsby PJ. P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci 2002:22:RC213 (full manuscript available at www.jneuroscir.org/cgi/content/full/6167).
87. Hagen K, Stovner LJ, Åsberg A, Thorstensen K, Bjerve KS, Hveem K. High headache prevalence among women with hemochromatosis: the Nord-Trøondelag Health Study. Ann Neurol 2002;51:786-789.
88. Goadsby PJ. How do currently used prophylactic agents work in migraine? Cephalalgia 1997;17:85-92.
89. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002;22:491-512.
90. Ramadan NM. Migraine prevention. In: Mancall EL ed. Continuum. Headache update. Philadelphia: Lippincott Williams & Wilkins, 2003:80-94.